Some pancreatic cancer patients can be relieved after targeted therapy and improve their prognosis, but the specific situation varies from person to person. Pancreatic cancer has a highly malignant biological behavior, and patients are still combined with a high risk of tumor recurrence after surgery, and some patients develop local recurrence or distant metastasis in the early postoperative period. For patients with locally progressive or metastatic pancreatic cancer, chemotherapy, targeted therapy, immunotherapy, etc. are important treatment tools. If the patient has gene mutation and other conditions, there are targeted drugs can be targeted therapy, such as erlotinib, olaparib, etc., which are mainly used in the treatment of advanced pancreatic cancer in the progressive stage, advanced stage, and advanced pancreatic cancer that has already appeared metastasis. Taking erlotinib as an example, a study that explored the combination of gemcitabine and erlotinib in the treatment of advanced pancreatic cancer showed that the objective response rate of patients was 14.4% , the disease control rate was 55.0%, the 1-year overall survival rate was 28.5% , the progression-free survival period was 2.63-9.60 months, and the overall survival period was 6-10 months. If pancreatic cancer is suspected or diagnosed, it is recommended to go to regular hospitals for comprehensive assessment of the disease, integrating multiple means of diagnosis and evaluation of the disease, and follow the doctor’s instructions to cooperate with the treatment to avoid delaying the disease. Please strictly follow the doctor’s instructions for medication, and do not use medication on your own.